• 1
    Murray EB. The life and times of the Enterococcus. Clinical Microbiol Rev 1990; 4665.
  • 2
    Recommendations for preventing the spread of vancomycin resistance. . Suppl. to MMWR 1995; 44(RR12): 113.
  • 3
    Keane WF, Alexander SR, Bailie GR, et al. Peritonial dialysis – related peritonitis treatment recommendations: 1996 Update. Perit Dial Int 1996; 16: 557573.
  • 4
    Anglim AM, Klym B, Byers KE, et al. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997; 157: 11321136.
  • 5
    Lipsky BA, Baker CA, McDonald LL, et al. Improving the appropriateness of vancomycin use by sequential intervention. Am J Infect Control 1999; 27: 8490.
  • 6
    Singer MV, Haft R, Barlam T, et al. Vancomycin control measures at a tertiary care hospital: impact of interventions on Volume and patterns of use. Infect Control Hosp Epidemiol 1998; 19: 248253.
  • 7
    Shojania KG, Yokoe D, Platt R, et al. Reducing vancomycin use utilizing a computer guideline. J Am Med Informatics Assoc 1998; 5: 554562.
  • 8
    Belongia EA & Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. Br Med J 1998; 317: 668671.
  • 9
    Hamilton CD, Drew R, Janning SW, et al. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol 2000; 21: 4245.
  • 10
    Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 3035.
  • 11
    Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of anti-microbial agents in neutropenic patients with unexplained fever. JID 1990; 161: 381396.
  • 12
    Maki DG, Bohn MJ, Stolz SM, et al. Comparative study of cefazolin, cefamandol, and vancomycin for surgical prophylaxis in cardiac and vascular operations;. J Thorac Cardiovasc Surg 1992; 104: 14231434.
  • 13
    Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. CID 1997; 25: 551573.
  • 14
    Mason AD, McManus AT, Pruitt BA. Association of burn mortality and bacteremia. A 25-Year Review. Arch Surg 1986; 121: 10271031.
  • 15
    Hunt JL, Purdue GF, Tuggle DW. Morbidity and mortality of an endemic pathogen: methicillin-resistant Staphylococcus aureus. Am J Surg 1988; 157: 524527.
  • 16
    De-Gorgolas M, Aviles P, Verdego C, et al. Treatment of experimental endocarditis due to methicillin-suscetible and methicillin-resistant S.aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthisis. Antimicrobial Agents Chemother 1995; 39: 953957.
  • 17
    De Silva N & Mendis LN. Comparison of minnimum inhibitory concentrations to methicillin in heterogenous and homogenous methicillin resistant S. Aureus. Ceylon Med J 1996; 41: 144147.
  • 18
    Alef K. Clostridium difficile-associated disease; implications for midwifery practice. J Nurse-Midwifery 1999; 44: 1929.
  • 19
    Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. CID 1997; 25: 247259.
  • 20
    Cui L, Kasegawa H, Murakami Y, et al. Postoperative toxic shock syndrome caused by a highly virulent methicillin-resistant Staphylococcus aureus strain. Scand J Infect Dis 1999; 31: 208209.